Harmony BiosciencesHRMY
HRMY
About: Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Employees: 268
0
Funds holding %
of 7,302 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
215% more call options, than puts
Call options by funds: $4.95M | Put options by funds: $1.57M
111% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 19
18% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 84
8% more funds holding
Funds holding: 245 [Q4 2024] → 265 (+20) [Q1 2025]
5.07% less ownership
Funds ownership: 92.42% [Q4 2024] → 87.35% (-5.07%) [Q1 2025]
8% less capital invested
Capital invested by funds: $1.81B [Q4 2024] → $1.66B (-$153M) [Q1 2025]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 3 (-1) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$48
48%
upside
Avg. target
$55
70%
upside
High target
$70
116%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Andreas Argyrides | 88%upside $61 | Outperform Assumed | 2 Jun 2025 |
Mizuho Graig Suvannavejh | 48%upside $48 | Outperform Maintained | 15 May 2025 |
Needham Ami Fadia | 51%upside $49 | Buy Reiterated | 7 May 2025 |
UBS Ashwani Verma | 48%upside $48 | Buy Maintained | 28 Apr 2025 |
HC Wainwright & Co. Patrick Trucchio | 116%upside $70 | Buy Reiterated | 8 Apr 2025 |
Financial journalist opinion
Based on 3 articles about HRMY published over the past 30 days
Neutral
Business Wire
1 week ago
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational, highly potent, and potentially best-in-class orexin 2 receptor (OX2R) agonist, which demonstrated significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model of narcolepsy type 1. The data will be presented at the 39th Annual Meeting of the Associated Professi.
Neutral
Business Wire
2 weeks ago
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin's Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the District of Delaware will be dismissed, and Lupin will receive a license to launch its generic product n.
Neutral
Business Wire
2 weeks ago
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL on Monday, June 9, 2025, at 3:20 p.m., ET A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutica.
Neutral
Seeking Alpha
1 month ago
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q1 2025 Earnings Call May 6, 2025 8:30 AM ET Company Participants Brennan Doyle - Head, Investor Relations Jeffrey Dayno - President and Chief Executive Officer Adam Zaeske - Chief Commercial Officer Kumar Budur - Chief Medical and Scientific Officer Sandip Kapadia - Chief Financial Officer Conference Call Participants Graig Suvannavejh - Mizuho Securities David Amsellem - Piper Sandler Ami Fadia - Needham Patrick Trucchio - H.C. Wainwright David Hoang - Deutsche Bank Ash Verma - UBS Jason Gerberry - Bank of America Charles Duncan - Cantor Fitzgerald Operator Good morning.
Positive
Zacks Investment Research
1 month ago
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.67 per share a year ago.
Neutral
Business Wire
1 month ago
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, on its way to a potential $1B+ opportunity in narcolepsy alone and poised for additional growth from its next-gen pitolisant development programs. The company has demonstrated four consecutive years of profitability and has grown its cash and investments position to over $600M. “Building off of our strong fou.
Positive
Zacks Investment Research
1 month ago
Why Harmony Biosciences (HRMY) Could Beat Earnings Estimates Again
Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Neutral
Business Wire
1 month ago
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-267-6316 (domestic) or 203-518-9783 (international), and reference passcode HRMYQ125. It is recommended that you dia.
Positive
Zacks Investment Research
1 month ago
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
Neutral
Accesswire
2 months ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Charts implemented using Lightweight Charts™